J
Julie Rivers
Researcher at Seattle Children's
Publications - 10
Citations - 381
Julie Rivers is an academic researcher from Seattle Children's. The author has contributed to research in topics: Antigen & Rituximab. The author has an hindex of 6, co-authored 8 publications receiving 249 citations. Previous affiliations of Julie Rivers include Seattle Children's Research Institute & University of Washington.
Papers
More filters
Journal ArticleDOI
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
Rebecca Gardner,Francesco Ceppi,Julie Rivers,Colleen Annesley,Corinne Summers,Agne Taraseviciute,Juliane Gust,Juliane Gust,Kasey J. Leger,Katherine Tarlock,Todd M. Cooper,Olivia Finney,Hannah Brakke,Daniel H. Li,Julie R. Park,Michael C. Jensen +15 more
TL;DR: The contention that early intervention with the use of tocilizumab and/or corticosteroids in subjects with early signs of CRS is without negative impact on anti-tumor potency of CD19CAR T cells is supported.
Journal ArticleDOI
Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
Francesco Ceppi,Francesco Ceppi,Julie Rivers,Julie Rivers,Colleen Annesley,Colleen Annesley,Navin Pinto,Navin Pinto,Julie R. Park,Julie R. Park,Catherine Lindgren,Stephanie Mgebroff,Naomi Linn,Meghan Delaney,Rebecca Gardner,Rebecca Gardner +15 more
TL;DR: The experience of collecting T lymphocytes for chimeric antigen receptor T‐cell manufacturing in pediatric and young adult patients with leukemia, non‐Hodgkin lymphoma, or neuroblastoma is reported.
Journal ArticleDOI
Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management
Rebecca Gardner,Rebecca Gardner,Kasey J. Leger,Colleen Annesley,Corinne Summers,Corinne Summers,Corinne Summers,Julie Rivers,Juliane Gust,Katherine Tarlock,Todd M. Cooper,Navin R. Pinto,Olivia Finney,Hannah Smithers,Assaf P. Oron,Daniel Li,Julie R. Park,Julie R. Park,Michael C. Jensen,Michael C. Jensen +19 more
TL;DR: Early intervention with immunomodulation appears to decrease the rates of sCRS while preserving the high rates of MRD-negative CR.
Journal ArticleDOI
Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia
Rebecca Gardner,Colleen Annesley,Olivia Finney,Corinne Summers,Adam J. Lamble,Julie Rivers,Kaelin Crews,Lauren Huang,Christopher Brown,Stephanie Mgebroff,Catherine Lindgren,Karen Spratt,Josh Gustafson,Adam Johnson,Julie R. Park,Michael C. Jensen +15 more
TL;DR: The primary objectives were to determine the feasibility of manufacturing products with dual specificity, to assess the safety of the cryopreserved product infusion, and to describe the full toxicity profile.
Journal ArticleDOI
Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells
Julie Rivers,Colleen Annesley,Colleen Annesley,Corinne Summers,Corinne Summers,Olivia Finney,Michael A. Pulsipher,Alan S. Wayne,Julie R. Park,Julie R. Park,Michael C. Jensen,Michael C. Jensen,Rebecca Gardner,Rebecca Gardner +13 more
TL;DR: SCRI-CAR19v1 therapy demonstrates efficacy in pediatric patients with relapsed and refractory NHL and appears to be well tolerated with less severe toxicities than observed for Pediatrics, with ongoing persistence at last check.